Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 11.1% during the second quarter, Holdings Channel reports. The fund owned 30,525 shares of the medical research company’s stock after selling 3,799 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Edwards Lifesciences Corporation were worth $3,609,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. South Texas Money Management Ltd. increased its position in shares of Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock worth $32,437,000 after buying an additional 211,119 shares during the period. Financial Counselors Inc. increased its position in shares of Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock worth $1,283,000 after buying an additional 282 shares during the period. American Century Companies Inc. increased its position in shares of Edwards Lifesciences Corporation by 7.2% in the first quarter. American Century Companies Inc. now owns 2,046,875 shares of the medical research company’s stock worth $192,550,000 after buying an additional 137,934 shares during the period. Advisor Partners LLC increased its position in shares of Edwards Lifesciences Corporation by 7.5% in the first quarter. Advisor Partners LLC now owns 4,895 shares of the medical research company’s stock worth $460,000 after buying an additional 341 shares during the period. Finally, Torch Wealth Management LLC purchased a new position in shares of Edwards Lifesciences Corporation during the first quarter worth approximately $1,635,000. 84.15% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Corporation (NYSE EW) opened at 114.50 on Friday. The firm has a market cap of $24.18 billion, a PE ratio of 34.73 and a beta of 0.63. The firm has a 50-day moving average price of $116.95 and a 200 day moving average price of $105.35. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. During the same quarter in the prior year, the business earned $0.76 earnings per share. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% on a year-over-year basis. Equities research analysts forecast that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.watchlistnews.com/edwards-lifesciences-corporation-ew-position-cut-by-mitsubishi-ufj-kokusai-asset-management-co-ltd/1481328.html.

EW has been the topic of a number of recent research reports. Vetr downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 target price on the stock. in a research note on Monday, May 15th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 target price on the stock in a research note on Monday, May 22nd. Goldman Sachs Group, Inc. (The) initiated coverage on Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 target price on the stock. Canaccord Genuity restated a “buy” rating and issued a $150.00 target price on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Finally, Barclays PLC boosted their target price on Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, July 27th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences Corporation presently has an average rating of “Buy” and an average target price of $121.13.

In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $118.05, for a total transaction of $3,883,845.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Patrick B. Verguet sold 11,500 shares of the stock in a transaction on Monday, May 15th. The shares were sold at an average price of $111.64, for a total transaction of $1,283,860.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 183,412 shares of company stock valued at $21,176,230. 2.13% of the stock is owned by company insiders.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.